WCP
REGN icon

Wick Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Wick Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$468K Buy
606
+171
+39% +$131K 0.09% 102
2025
Q4 		$336K Buy
+435
New +$295K 0.06% 132

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wick Capital Partners's REGN Position: Q1 2026 in Review

Wick Capital Partners increased its Regeneron Pharmaceuticals (REGN) stake by 39% in Q1 2026, buying an estimated $131K and bringing the position to 606 shares worth $468K. The position accounts for 0.09% of the portfolio, ranked #102.

Wick Capital Partners first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Wick Capital Partners held 606 shares of Regeneron Pharmaceuticals worth $468K as of Q1 2026.
  • Wick Capital Partners bought 171 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $131K.
  • Regeneron Pharmaceuticals made up 0.09% of Wick Capital Partners's portfolio in Q1 2026, its #102 holding.
  • Wick Capital Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Wick Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.